
Opinion|Videos|June 11, 2024
Results from CROWN: Lorlatinib in Treatment-Naïve Patients with Advanced ALK+ NSCLC
The Oncology Brothers and Joshua K. Sabari, MD, provide expert perspectives on recent updates from the CROWN trial investigating lorlatinib in treatment-naïve advanced ALK+ non–small cell lung cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















